BOCH
Blue Owl Capital Holdings Portfolio holdings
AUM
$310M
This Quarter Return
-2.93%
1 Year Return
+6.98%
3 Year Return
+59.66%
5 Year Return
–
10 Year Return
–
AUM
$434M
AUM Growth
+$434M
(-16%)
Cap. Flow
-$45.2M
Cap. Flow
% of AUM
-10.42%
Top 10 Holdings %
Top 10 Hldgs %
71.48%
Holding
147
New
10
Increased
10
Reduced
15
Closed
68
Top Buys
| 1 |
Conduent
CNDT
|
$9.14M |
| 2 |
Eledon Pharmaceuticals
ELDN
|
$8.07M |
| 3 |
Tango Therapeutics
TNGX
|
$5.35M |
| 4 |
EyePoint Pharmaceuticals
EYPT
|
$4.97M |
| 5 |
Cullinan Oncology
CGEM
|
$4.38M |
Top Sells
| 1 |
ProShares UltraPro QQQ
TQQQ
|
$23.6M |
| 2 |
Tourmaline Bio
TRML
|
$9.15M |
| 3 |
LanzaTech
LNZA
|
$5.59M |
| 4 |
CCC Intelligent Solutions
CCCS
|
$5.05M |
| 5 |
Klaviyo
KVYO
|
$4.93M |
Sector Composition
| 1 | Healthcare | 50.71% |
| 2 | Financials | 25.62% |
| 3 | Technology | 21% |
| 4 | Consumer Discretionary | 2.08% |
| 5 | Energy | 0.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Nuveen Churchill Direct Lending
NCDL
$789M
| $67.8M | 15.62% | 4,039,553 | – | – |
|
|
2
Klaviyo
KVYO
$9.73B
| $44.5M | 10.25% | 1,078,770 -119,500 | -10% | -$4.93M |
|
3
Pliant Therapeutics
PLRX
$101M
| $36.5M | 8.4% | 2,769,199 -235,000 | -8% | -$3.09M |
|
4
Blue Owl Capital
OBDC
$7.33B
| $30.9M | 7.12% | 2,045,070 | – | – |
|
|
5
Cullinan Oncology
CGEM
$445M
| $28.9M | 6.65% | 2,370,972 +360,000 | +18% | +$4.38M |
|
|
6
Conduent
CNDT
$439M
| $22.7M | 5.24% | 5,625,459 +2,262,437 | +67% | +$9.14M |
|
|
7
Tourmaline Bio
TRML
$601M
| $21.9M | 5.04% | 1,079,321 -451,080 | -29% | -$9.15M |
|
8
enGene Holdings
ENGN
$236M
| $21M | 4.84% | 3,159,975 +101,006 | +3% | +$672K |
|
9
EverCommerce
EVCM
$2.09B
| $18.1M | 4.17% | 1,641,929 | – | – |
|
10
Larimar Therapeutics
LRMR
$310M
| $18M | 4.15% | 4,653,040 +486,211 | +12% | +$1.88M |
|
11
GoHealth
GOCO
$81.7M
| $11.1M | 2.57% | 83,264 | – | – |
|
12
Holley
HLLY
$490M
| $9.03M | 2.08% | 2,990,294 +446,706 | +18% | +$1.35M |
|
|
SLRN
13
DELISTED
ACELYRIN
SLRN
| $8.74M | 2.01% | 2,783,946 -10,000 | -0.4% | -$31.4K |
|
|
14
Eledon Pharmaceuticals
ELDN
$155M
| $8.07M | 1.86% | +1,959,912 | New | +$8.07M |
|
15
Disc Medicine
IRON
$2.07B
| $7.62M | 1.76% | 120,260 -55,000 | -31% | -$3.49M |
|
|
IMA
16
ImageneBio, Inc. Common Stock
IMA
$150M
| $6.71M | 1.55% | 4,091,118 | – | – |
|
17
Context Therapeutics
CNTX
$75.4M
| $6.68M | 1.54% | 6,357,928 +946,638 | +17% | +$994K |
|
18
Sagimet Biosciences
SGMT
$244M
| $5.96M | 1.37% | 1,323,877 -350,000 | -21% | -$1.58M |
|
|
19
Tango Therapeutics
TNGX
$747M
| $5.35M | 1.23% | +1,732,152 | New | +$5.35M |
|
20
Ultragenyx Pharmaceutical
RARE
$2.89B
| $4.97M | 1.15% | 118,238 -45,000 | -28% | -$1.89M |
|
|
21
EyePoint Pharmaceuticals
EYPT
$797M
| $4.97M | 1.15% | +667,594 | New | +$4.97M |
|
22
Repare Therapeutics
RPTX
$71.7M
| $4.51M | 1.04% | 3,443,659 +71,160 | +2% | +$93.2K |
|
|
ETWO
23
DELISTED
E2open Parent Holdings
ETWO
| $4.39M | 1.01% | 1,650,943 | – | – |
|
24
Compass Therapeutics
CMPX
$483M
| $4.28M | 0.99% | 2,954,712 +75,000 | +3% | +$109K |
|
25
Keros Therapeutics
KROS
$618M
| $3.84M | 0.89% | 242,633 +120,000 | +98% | +$1.9M |
|